Article
Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the SOPHIA study.
Pharmacogenomics - 1 Sept 2014
Frau Francesca, Zaninello Roberta, Salvi Erika, Ortu Maria Francesca, Braga Daniele, Velayutham Dinesh, Argiolas Giuseppe, Fresu Giovanni, Troffa Chiara, Bulla Emanuela, Bulla Patrizia, Pitzoi Silvia, Piras Daniela Antonella, Glorioso Valeria, Chittani Martina, Bernini Giampaolo, Bardini Michele, Fallo Francesco, Malatino Lorenzo, Stancanelli Benedetta, Regolisti Giuseppe, Ferri Claudio, Desideri Giovanbattista, Scioli Giuseppe Antonio, Galletti Ferruccio, Sciacqua Angela, Perticone Francesco, Degli Esposti Ezio, Sturani Alessandra, Semplicini Andrea, Veglio Franco, Mulatero Paolo, Williams Tracy A, Lanzani Chiara, Hiltunen Timo P, Kontula Kimmo, Boerwinkle Eric, Turner Stephen T, Manunta Paolo, Barlassina Cristina, Cusi Daniele, Glorioso Nicola
Abstract excerpt
BACKGROUND: Essential hypertension arises from the combined effect of genetic and environmental factors. A pharmacogenomics approach could help to identify additional molecular mechanisms involved in its pathogenesis. AIM: The aim of SOPHIA study was to identify genetic polymorphisms regulating blood pressure response to the angiotensin II receptor blocker, losartan, with a whole-genome approach. MATERIALS &...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.